The safety of hormonal menopausal therapy Review article
Article Sidebar
Published:
Jun 30, 2019
Keywords:
hormone menopausal therapy, menopause, cardiovascular risk, cancer, estrogen, progesterone
Main Article Content
Abstract
Hormonal menopausal therapy is used to relieve the age-related symptoms of natural changes in hormonal management. Additionally, it can reduce the risk of cardiovascular and cervical cancer. The risk of adverse reactions can be reduced through the choosing appropriate preparation, dose, and form of administration.
Article Details
How to Cite
Skrzypulec-Plinta, V., Jagiełło-Gruszfeld, A., Śliż , D., & Mamcarz , A. (2019). The safety of hormonal menopausal therapy. Medycyna Faktow (J EBM), 12(2(43), 120-124. https://doi.org/10.24292/01.MF.0219.6
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Temkin S.M., Mallen A., Bellavance E. et al.: The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions. Cancer 2018. DOI: 10.1002/cncr.31911. [Epub ahead of print].
2. Chan L.Y., Yuen P.M.: Influence of the Women’s Health Initiative trial on the practice of prophylactic oophorectomy and the prescription of estrogen therapy. Fertil. Steril. 2004; 81: 1699-1700.
3. Lupo M., Dains J.E., Madsen L.T.: Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients? J. Adv. Pract. Oncol. 2015; 6(4): 322-330.
4. Palacios S, Mejia A. Progestogen safety and tolerance in hormonal replacement therapy. Expert Opin. Drug Saf. 2016; 15: 1515-1525.
5. Kotsopoulos J., Gronwald J., Karlan B.Y. et al.: Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018; 4: 1059-1065.
6. Marchetti C., De Felice F., Boccia S. et al.: Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit. Rev. Oncol. Hematol. 2018 132:111-115. doi: 10.1016/j.critrevonc.2018.09.018.
7. Angiolia R., Luveroa D., Armentob G. et al.: Hormone replacement therapy in cancer survivors: Utopia? Crit. Rev. Oncol. Hematol. 2018; 124: 51-60.
8. Kuhle C.L., Kapoor E., Richa Sood R. et al.: Menopausal hormone therapy in cancer survivors: A narrative review of the literature. Maturitas 2016; 92: 86-96.
9. Fahlen M., Fornander T., Johansson H. et al.: Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur. J. Cancer 2013; 49: 52-59.
10. Whicker M., Black J., Altwerger G. et al.: Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am. J. Obstet. Gynecol. 2017: 395-403.
11. Stampfer M., Colditz G.: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine 1991; 20: 47‐63.
12. Psaty B.M., Heckbert S.R., Atkins D. et al.: The risk of myocardial infarction associated with the combined use of estrogen and progestins in postmenopausal women. Arch. Intern. Med. 1994; 154(12): 1333‐1339.
13. Hulley S., Grady D., Bush T. et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280(7): 605‐613.
14. Grady D., Wenger N., Herrington D. et al.: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann. Intern. Med. 2000; 132: 689‐696.
15. Rossouw J., Anderson G., Prentice R. et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288(3): 321‐333.
16. Cushman M., Kuller L.H., Prentice R. et al.: Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292(13): 1573‐1580.
17. Rossouw J.E., Prentice R.L., Manson J.E. et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297(13): 1465-1477.
18. Schierbeck L.L., Rejnmark L., Tofteng C.L. et al.: Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409.
19. Boardman H.M.P., Hartley L., Eisinga A. et al.: Hormone therapy for preventing cardiovascular disease in post‐menopausal women. Cochrane Database of Systematic Reviews 2015; Issue 3. Art. No.: CD002229. DOI: 10.1002/14651858.CD002229.pub4.
20. Dębski R.: Endokrynologia ginekologiczna. PZWL, Warszawa 2018.
21. Zborowska K., Skrzypulec-Plinta V., Sarnik A.: Bezpieczeństwo stosowania terapii hormonalnej wieku menopauzalnego. Forum Położnictwa i Ginekologii 2018; 42/464442: 57-64.
22. Rekomendacje Polskiego Towarzystwa Ginekologicznego 2006–2011. Progestageny w hormonalnej terapii zastępczej. Ginekologia Polska 2006; 77: 743-745.
23. Rekomendacje Polskiego Towarzystwa Menopauzy i Andropauzy na temat hormonalnej terapii menopauzy. Przegląd Menopauzalny 2014; 18(1): 1-8.
24. The 2017 Hormone therapy position statement of The North American Menopause Society. The NAMS2017 Hormone Therapy Position Statement Advisory Panel. Menopause 2017; 24(7): 728-753.
25. Fournier A., Fabre A., Mesrine S. et al.: Use of different postmenopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer. J. Clin. Oncol. 2008; 26: 1260-1268.
2. Chan L.Y., Yuen P.M.: Influence of the Women’s Health Initiative trial on the practice of prophylactic oophorectomy and the prescription of estrogen therapy. Fertil. Steril. 2004; 81: 1699-1700.
3. Lupo M., Dains J.E., Madsen L.T.: Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients? J. Adv. Pract. Oncol. 2015; 6(4): 322-330.
4. Palacios S, Mejia A. Progestogen safety and tolerance in hormonal replacement therapy. Expert Opin. Drug Saf. 2016; 15: 1515-1525.
5. Kotsopoulos J., Gronwald J., Karlan B.Y. et al.: Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018; 4: 1059-1065.
6. Marchetti C., De Felice F., Boccia S. et al.: Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit. Rev. Oncol. Hematol. 2018 132:111-115. doi: 10.1016/j.critrevonc.2018.09.018.
7. Angiolia R., Luveroa D., Armentob G. et al.: Hormone replacement therapy in cancer survivors: Utopia? Crit. Rev. Oncol. Hematol. 2018; 124: 51-60.
8. Kuhle C.L., Kapoor E., Richa Sood R. et al.: Menopausal hormone therapy in cancer survivors: A narrative review of the literature. Maturitas 2016; 92: 86-96.
9. Fahlen M., Fornander T., Johansson H. et al.: Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur. J. Cancer 2013; 49: 52-59.
10. Whicker M., Black J., Altwerger G. et al.: Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am. J. Obstet. Gynecol. 2017: 395-403.
11. Stampfer M., Colditz G.: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine 1991; 20: 47‐63.
12. Psaty B.M., Heckbert S.R., Atkins D. et al.: The risk of myocardial infarction associated with the combined use of estrogen and progestins in postmenopausal women. Arch. Intern. Med. 1994; 154(12): 1333‐1339.
13. Hulley S., Grady D., Bush T. et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280(7): 605‐613.
14. Grady D., Wenger N., Herrington D. et al.: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann. Intern. Med. 2000; 132: 689‐696.
15. Rossouw J., Anderson G., Prentice R. et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288(3): 321‐333.
16. Cushman M., Kuller L.H., Prentice R. et al.: Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292(13): 1573‐1580.
17. Rossouw J.E., Prentice R.L., Manson J.E. et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297(13): 1465-1477.
18. Schierbeck L.L., Rejnmark L., Tofteng C.L. et al.: Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409.
19. Boardman H.M.P., Hartley L., Eisinga A. et al.: Hormone therapy for preventing cardiovascular disease in post‐menopausal women. Cochrane Database of Systematic Reviews 2015; Issue 3. Art. No.: CD002229. DOI: 10.1002/14651858.CD002229.pub4.
20. Dębski R.: Endokrynologia ginekologiczna. PZWL, Warszawa 2018.
21. Zborowska K., Skrzypulec-Plinta V., Sarnik A.: Bezpieczeństwo stosowania terapii hormonalnej wieku menopauzalnego. Forum Położnictwa i Ginekologii 2018; 42/464442: 57-64.
22. Rekomendacje Polskiego Towarzystwa Ginekologicznego 2006–2011. Progestageny w hormonalnej terapii zastępczej. Ginekologia Polska 2006; 77: 743-745.
23. Rekomendacje Polskiego Towarzystwa Menopauzy i Andropauzy na temat hormonalnej terapii menopauzy. Przegląd Menopauzalny 2014; 18(1): 1-8.
24. The 2017 Hormone therapy position statement of The North American Menopause Society. The NAMS2017 Hormone Therapy Position Statement Advisory Panel. Menopause 2017; 24(7): 728-753.
25. Fournier A., Fabre A., Mesrine S. et al.: Use of different postmenopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer. J. Clin. Oncol. 2008; 26: 1260-1268.